Nearly 600 attendees learned about life sciences industry trends and heard from 93 presenting biotechnology companies at ...

The drive revolves around a "10-for-one" policy laid out in a Trump executive order at the end of January, which demanded ...

His time at Pfizer has coincided with the spectacular success of its BioNTech-partnered mRNA vaccine for COVID-19 – Comirnaty – and as GSK itself struggled to make headway with its own ...

With vaccine hesitancy leading to a rise in measles ... Numbers have since fallen, probably at least in part because of coronavirus-related lockdowns, coming in 13 cases in 2020 and 49 in 2021 ...

The COVID-19 pandemic underscored the urgency for swift, scalable drug production, sparking a surge in investment toward new production facilities. The demand for these facilities shows no signs ...

Vinay Prasad will replace Marks as CBER director Trump's budget would be "catastrophic" for federal R&D Pharma still in waiting mode after UK-US trade agreement ...

Novartis' soon-to-be-divested Sandoz unit has positive clinical trial data in hand for a biosimilar of Amgen's blockbuster osteoporosis therapy Prolia (denosumab), clearing the way for regulatory ...

In the space of four days, the number of FDA-approved therapies for ultra-rare genetic disorder Niemann-Pick disease has gone from zero to two, transforming the prospects for patients. IntraBio's ...

AstraZeneca has formed a partnership with Regeneron to investigate the potential of treating obesity using drugs directed at GPR75, a protective gene identified by scientists at the Regeneron ...

Maria joined AstraZeneca in 2017 as head of Respiratory, Inflammation & Autoimmunity in the Innovative Medicines and Early Development (IMED) Biotech Unit. In her role she leads early-stage ...

Japanese drugmaker Takeda has suffered a blow to its late-stage pipeline, after the FDA rejected its marketing application for TAK-721, a drug candidate that is trying to be the first approved ...